Top

Journal of Diabetes & Metabolic Disorders

Published in:

01-06-2021 | Obesity | Research article

The dynamics of metabolic syndrome development from its isolated components among Iranian adults: findings from 17 years of the Tehran lipid and glucose study (TLGS)

Authors: Davood Khalili, Pezhman Bagheri, Mozhgan Seif, Abbas Rezaianzadeh, Esmaeil Khedmati Morasae, Ehsan Bahramali, Fereidoun Azizi

Published in: Journal of Diabetes & Metabolic Disorders | Issue 1/2021

Abstract

Background

Evaluating the process of changes in the Metabolic Syndrome (MetS) components over time is one of the ways to study of the MetS natural history. This study aimed to determine the trend of changes in the progression of MetS from its isolated components.

Methods

This longitudinal study was performed on four follow-up periods of the Tehran Lipid and Glucose Study (TLGS) between 1999 and 2015. The research population consisted of 3905 adults over the age of 18 years. MetS was diagnosed based on the Joint Interim Statement (JIS). The considered components were abdominal obesity, hypertension, hyperglycemia, and dyslipidemia.

Results

The highest incidence of MetS from its components was related to hypertension in the short term (3.6-year intervals). In the long run, however, the highest increase in the MetS incidence occurred due to abdominal obesity. Overall, the incidence of MetS increased due to obesity and dyslipidemia, but decreased due to the other factors. Nonetheless, the trend of MetS incidence from all components increased in total. The most common components were dyslipidemia with a decreasing trend and obesity with an increasing trend during the study.

Conclusion

The results indicated that obesity and hypertension components played a more important role in the further development of MetS compared to other components in the Iranian adult population. This necessitates careful and serious attention in preventive and control planning.

Zafar U, Khaliq S, Ahmad HU, Manzoor S, Lone KP. Metabolic syndrome: an update on diagnostic criteria, pathogenesis, and genetic links. Hormones (Athens, Greece). 2018;17(3):299–313.CrossRef

Zambon S, Zanoni S, Romanato G, Corti MC, Noale M, Sartori L, et al. Metabolic syndrome and all-cause and cardiovascular mortality in an Italian elderly population: the Progetto Veneto Anziani (pro.V.a.) study. Diabetes Care. 2009;32(1):153–9.PubMedCrossRef

Ford ES. Risks for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome: a summary of the evidence. Diabetes Care. 2005;28(7):1769–78.PubMedCrossRef

Alberti KG, Zimmet P, Shaw J. The metabolic syndrome--a new worldwide definition. Lancet (London, England). 2005;366(9491):1059–62.CrossRef

Carnethon M, Loria C, Hill J, Sidney S, Savage P, Liu K. Risk factors for the metabolic syndrome the coronary artery risk development in young adults (CARDIA) study, 1985–2001. Diabetes Care. 2004;27:2707–15.PubMedCrossRef

Li R, Li W, Lun Z, Zhang H, Sun Z, Kanu JS, et al. Prevalence of metabolic syndrome in Mainland China: a meta-analysis of published studies. BMC Public Health. 2016;16:296.PubMedCrossRef

Wu LT, Shen YF, Hu L, Zhang MY, Lai XY. Prevalence and associated factors of metabolic syndrome in adults: a population-based epidemiological survey in Jiangxi province. China BMC Public Health. 2020;20(1):133.PubMedCrossRef

Kuzuya M, Ando F, Iguchi A, Shimokata H. Age-specific change of prevalence of metabolic syndrome: longitudinal observation of large Japanese cohort. Atherosclerosis. 2007;191(2):305–12.PubMedCrossRef

Van Hemelrijck M, Ulmer H, Nagel G, Peter R, Fritz J, Myte R, et al. Longitudinal study of body mass index, dyslipidemia, hyperglycemia, and hypertension in 60,000 men and women in Sweden and Austria. PLoS One. 2018;13:e0197830.PubMedCrossRef

10.

Lee M-K, Han K, Kim MK, Koh ES, Kim ES, Nam GE, et al. Changes in metabolic syndrome and its components and the risk of type 2 diabetes: a nationwide cohort study. Sci Rep. 2020;10(1):2313.PubMedCrossRef

11.

Huh JH, Ahn SG, Kim YI, Go T, Sung KC, Choi JH, et al. Impact of longitudinal changes in metabolic syndrome status over 2 years on 10-year incident diabetes mellitus. Diabetes Metab J. 2019;43(4):530–8.PubMedCrossRef

12.

Ingelsson E, Pencina MJ, Tofler GH, Benjamin EJ, Lanier KJ, Jacques PF, et al. Multimarker approach to evaluate the incidence of the metabolic syndrome and longitudinal changes in metabolic risk factors. Circulation. 2007;116(9):984–92.PubMedCrossRef

13.

Jia X, Chen Q, Wu P, Liu M, Chen X, Xiao J, et al. Dynamic development of metabolic syndrome and its risk prediction in Chinese population: a longitudinal study using Markov model. Diabetol Metab Syndr. 2018;10:24.PubMedCrossRef

14.

Hwang L-C, Bai C-H, You S-L, Sun C-A, Chen C-J. Description and prediction of the development of metabolic syndrome: a longitudinal analysis using a Markov model approach. PLoS One. 2013;8(6):e67436.PubMedCrossRef

15.

Haring R, Rosvall M, Völker U, Völzke H, Kroemer H, Nauck M, et al. A network-based approach to visualize prevalence and progression of metabolic syndrome components. PLoS One. 2012;7(6):e39461.PubMedCrossRef

16.

Barcelo MA, Rodriguez-Poncelas A, Saez M, Coll-de-Tuero G. The dynamic behaviour of metabolic syndrome and its components in an eight-year population-based cohort from the Mediterranean. PLoS One. 2017;12(5):e0176665.PubMedCrossRef

17.

DeFronzo RA, Ferrannini E. Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care. 1991;14(3):173–94.PubMedCrossRef

18.

Azizi F, Zadeh-Vakili A, Takyar M. Review of Rationale, Design, and Initial Findings: Tehran Lipid and Glucose Study. Int J Endocrinol Metab. 2018;16(4 (Suppl)):e84777.PubMedPubMedCentral

19.

Azizi F. Tehran Lipid and Glucose Study: A National Legacy. Int J Endocrinol Metab. 2018;16(4 Suppl):e84774-e.

20.

Azizi F. Tehran lipid and glucose study: a legacy for prospective community-based research. Archives of Iranian medicine. 2014;17(6):392–3.PubMed

21.

Huque MH, Moreno-Betancur M, Quartagno M, Simpson JA, Carlin JB, Lee KJ. Multiple imputation methods for handling incomplete longitudinal and clustered data where the target analysis is a linear mixed effects model. Biometric J Biometrische Zeitschrift. 2020;62(2):444–66.CrossRef

22.

Huque MH, Carlin JB, Simpson JA, Lee KJ. A comparison of multiple imputation methods for missing data in longitudinal studies. BMC Med Res Methodol. 2018;18(1):168.PubMedCrossRef

23.

De Silva AP, Moreno-Betancur M, De Livera AM, Lee KJ, Simpson JA. Multiple imputation methods for handling missing values in a longitudinal categorical variable with restrictions on transitions over time: a simulation study. BMC Med Res Methodol. 2019;19(1):14.PubMedCrossRef

24.

De Silva AP, Moreno-Betancur M, De Livera AM, Lee KJ, Simpson JA. A comparison of multiple imputation methods for handling missing values in longitudinal data in the presence of a time-varying covariate with a non-linear association with time: a simulation study. BMC Med Res Methodol. 2017;17(1):114.PubMedCrossRef

25.

Patrician PA. Multiple imputation for missing data. Res nursing health. 2002;25(1):76–84.CrossRef

26.

Duffy ME. Handling missing data: a commonly encountered problem in quantitative research. Clinical nurse specialist CNS. 2006;20(6):273–6.PubMedCrossRef

27.

El-Masri MM, Fox-Wasylyshyn SM (2005) Missing data: an introductory conceptual overview for the novice researcher. The Canadian journal of nursing research = Revue canadienne de recherche en sciences infirmieres;37(4):156–71.

28.

Alberti KGMM, Eckel Robert H, Grundy Scott M, Zimmet Paul Z, Cleeman James I, Donato Karen A, et al. Harmonizing the metabolic syndrome. Circulation. 2009;120(16):1640–5.PubMedCrossRef

29.

Hosseini-Esfahani F, Bahadoran Z, Moslehi N, Asghari G, Yuzbashian E, Hosseinpour-Niazi S, et al. Metabolic Syndrome: Findings from 20 Years of the Tehran Lipid and Glucose Study. Int J Endocrinol Metab. 2018;16(4 Suppl):e84771-e.

30.

Azizi F, Khalili D, Aghajani H, Esteghamati A, Hosseinpanah F, Delavari A, et al. Appropriate waist circumference cut-off points among Iranian adults: the first report of the Iranian National Committee of obesity. Archives of Iranian medicine. 2010;13(3):243–4.PubMed

31.

Rose GA, Blackburn H. Cardiovascular survey methods. Monograph series World Health Org. 1968;56:1–188.

32.

Ainsworth BE, Jacobs DR Jr, Leon AS. Validity and reliability of self-reported physical activity status: the lipid research clinics questionnaire. Med Sci Sports Exerc. 1993;25(1):92–8.PubMedCrossRef

33.

Center AC (1997) ARIC Manuals of Operation: Cohort component procedures. (2)

34.

Ma W-Y, Yang C-Y, Shih S-R, Hsieh H-J, Hung CS, Chiu F-C, Lin MS, Liu PH, Hua CH, Hsein YC, Chuang LM, Lin JW, Wei JN, Li HY Measurement of waist circumference: midabdominal or iliac crest? Diabetes Care 2013;36(6):1660–6, 1666.

35.

Scuteri A, Morrell CH, Najjar SS, Muller D, Andres R, Ferrucci L, et al. Longitudinal paths to the metabolic syndrome: can the incidence of the metabolic syndrome be predicted? The Baltimore longitudinal study of aging. J Gerontol A Biol Sci Med Sci. 2009;64(5):590–8.PubMedCrossRef

36.

Sarebanhassanabadi M, Jalil Mirhosseini S, Mirzaei M, Namayandeh SM, Soltani MH, Pedarzadeh A, et al. The incidence of metabolic syndrome and the Most powerful components as predictors of metabolic syndrome in Central Iran: a 10-year follow-up in a cohort study. Iran Red Crescent Med J. 2017;19(7):e14934.CrossRef

37.

Janghorbani M, Amini M. Incidence of metabolic syndrome and its risk factors among type 2 diabetes clinic attenders in Isfahan. Iran Endokrynologia Polska. 2012;63(5):372–80.PubMed

38.

Jiang B, Li B, Wang Y, Han B, Wang N, Li Q, et al. The nine-year changes of the incidence and characteristics of metabolic syndrome in China: longitudinal comparisons of the two cross-sectional surveys in a newly formed urban community. Cardiovasc Diabetol. 2016;15:84.PubMedCrossRef

39.

Hadaegh F, Hasheminia M, Lotfaliany M, Mohebi R, Azizi F, Tohidi M. Incidence of metabolic syndrome over 9 years follow-up; the importance of sex differences in the role of insulin resistance and other risk factors. PloS one. 2013;8(9):e76304-e.CrossRef

40.

Zabetian A, Hadaegh F, Sarbakhsh P, Azizi F. Weight change and incident metabolic syndrome in Iranian men and women; a 3 year follow-up study. BMC Public Health. 2009;9:138.PubMedCrossRef

41.

Santos AC, Severo M, Barros H. Incidence and risk factors for the metabolic syndrome in an urban south European population. Prev Med. 2010;50(3):99–105.PubMedCrossRef

42.

Balkau B, Vernay M, Mhamdi L, Novak M, Arondel D, Vol S, et al. The incidence and persistence of the NCEP (National Cholesterol Education Program) metabolic syndrome. The French D.E.S.I.R. study. Diabetes Metab. 2003;29(5):526–32.PubMedCrossRef

43.

Li Y, Yatsuya H, Iso H, Tamakoshi K, Toyoshima H. Incidence of metabolic syndrome according to combinations of lifestyle factors among middle-aged Japanese male workers. Prev Med. 2010;51(2):118–22.PubMedCrossRef

44.

Tang X, Liu Q. Prediction of the development of metabolic syndrome by the Markov model based on a longitudinal study in Dalian City. BMC Public Health. 2018;18(1):707.PubMedCrossRef

45.

Palaniappan L, Carnethon MR, Wang Y, Hanley AJG, Fortmann SP, Haffner SM, et al. Predictors of the incident metabolic syndrome in adults. Diabetes Care. 2004;27(3):788–93.PubMedCrossRef

46.

Chen X, Chen Q, Chen L, Zhang P, Xiao J, Wang S. Description and prediction of the development of metabolic syndrome in Dongying City: a longitudinal analysis using the Markov model. BMC Public Health. 2014;14:1033.PubMedCrossRef

47.

Klop B, Elte JWF, Cabezas MC. Dyslipidemia in obesity: mechanisms and potential targets. Nutrients. 2013;5(4):1218–40.PubMedPubMedCentralCrossRef

Title: The dynamics of metabolic syndrome development from its isolated components among Iranian adults: findings from 17 years of the Tehran lipid and glucose study (TLGS)
Authors: Davood Khalili
Pezhman Bagheri
Mozhgan Seif
Abbas Rezaianzadeh
Esmaeil Khedmati Morasae
Ehsan Bahramali
Fereidoun Azizi
Publication date: 01-06-2021
Publisher: Springer International Publishing
Keywords: Obesity
Obesity
Dyslipidemia
Hyperglycemia
Hypertension
Hypertension
Published in: Journal of Diabetes & Metabolic Disorders / Issue 1/2021
Electronic ISSN: 2251-6581
DOI: https://doi.org/10.1007/s40200-020-00717-8

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

The dynamics of metabolic syndrome development from its isolated components among Iranian adults: findings from 17 years of the Tehran lipid and glucose study (TLGS)

Abstract

Background

Methods

Results

Conclusion

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2021

Association study between superoxide Dismutases gene polymorphisms and development of diabetic retinopathy and cataract in Iranian patients with type two diabetes mellitus

Effectiveness of an adapted diabetes nutrition education program on clinical status, dietary behaviors and behavior mediators in adults with type 2 diabetes: a randomized controlled trial

Correction to: Concurrent metformin and silibinin therapy in diabetes: assessments in zebrafish (Danio rerio) animal model

Role of interdigital sensory nerve conduction study as a noninvasive approach for early diagnosis of diabetic peripheral neuropathy

Prospection of plasma proteins as biomarkers for diabetes mellitus monitoring

Proportion and mortality of Iranian diabetes mellitus, chronic kidney disease, hypertension and cardiovascular disease patients with COVID-19: a meta-analysis

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page